Answers are grounded in this paper and cite their sources.
Animal study reveals ipragliflozin improves nonalcoholic steatohepatitis pathogenesis in mice, suggesting therapeutic efficacy for fatty liver disease with type 2 diabetes.
Ipragliflozin improved the pathogenesis of NASH by reducing insulin resistance and lipotoxicity in NASH-model mice. Our results suggest that ipragliflozin has a therapeutic effect on NASH with T2DM.
No takes yet. Share an insight, caveat, or question.
Honda et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: